Drug Trial Radar · NCT05515367
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,004
Planned (sponsor's estimate)
Start
Apr 20, 2023
Primary completion
Jun 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Zydus Lifesciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)
Conditions
- Chronic Kidney Diseases
- Anemia of Chronic Kidney Disease
Interventions
DesidustatDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To asses the Proportion of Subjects with treatment emergent adverse events.Time frame: Baseline (week 0) to Week 52 (end of treatment)
- To asses the Proportion of Subjects with treatment emergent Serious adverse events.Time frame: Baseline (week 0) to Week 52 (end of treatment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indira Gandhi Institute of Medical Sciences
Sheikhpura, Bihar, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.